Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH4: Ruxolitinib plus corticosteroids in pediatric acute GVHD after allo-HSCT
jRCT2080224560Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (4 cohorts), sponsored by Novartis. Primary endpoints: Pharmacokinetics of ruxolitinib, Efficacy of ruxolitinib in acute GVHD and 1 more. Started Feb 2019; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on jRCT2080224560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224560.